Top Page
Vitasora Health
(OTC:VHL)
Vitasora Health (VHL) vs. iShares MSCI Australia ETF (EWA)
Vitasora Health Business Overview & Revenue Model
Vitasora Health Financial Statement Overview
| Breakdown |
|---|
Income Statement |
| Total Revenue |
| Gross Profit |
| EBITDA |
| Net Income |
Balance Sheet |
| Total Assets |
| Cash, Cash Equivalents and Short-Term Investments |
| Total Debt |
| Total Liabilities |
| Stockholders Equity |
Cash Flow |
| Free Cash Flow |
| Operating Cash Flow |
| Investing Cash Flow |
| Financing Cash Flow |
Vitasora Health Technical Analysis
Vitasora Health Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | AU$44.04M | ― | -50.50% | ― | 39.08% | 53.31% | |
54 Neutral | AU$60.55M | ― | -8.08% | ― | -5.62% | -225.71% | |
54 Neutral | $103.40M | ― | -51.08% | ― | 10.22% | -2.94% | |
51 Neutral | $7.30B | 0.27 | -62.71% | 2.44% | 15.02% | 0.60% | |
49 Neutral | AU$55.38M | ― | -135.33% | ― | -27.58% | 33.69% | |
46 Neutral | AU$148.80M | ― | -58.61% | ― | ― | -74.88% | |
41 Neutral | AU$48.12M | ― | -185.67% | ― | 492.19% | 12.16% |
Vitasora Health Corporate Events
Vitasora Health Limited has announced its upcoming General Meeting scheduled for September 2025, which will be held virtually. Shareholders are encouraged to participate by voting via proxy or attending the virtual meeting to discuss and vote on proposed resolutions. This move reflects the company’s commitment to engaging with its stakeholders while adapting to modern, digital meeting formats.
Vitasora Health Limited has announced an Extraordinary General Meeting to be held virtually on September 1, 2025, where shareholders can vote on the ratification of a prior issue of shares. This meeting is significant as it involves the approval of 124,016,673 shares issued to investors, which could impact the company’s financial structure and market positioning.
Vitasora Health Limited reported significant growth in patient programs and revenue for the quarter ending June 2025, with a 226% increase in patient numbers and a 429% year-on-year revenue growth. The company has expanded its client base, launched new services, and made advancements in AI and automation, positioning itself strongly for future growth and shareholder value.
Vitasora Health Limited has experienced a change in the interests of its substantial holder, Legacy OH Holdings Inc., as of July 8, 2025. The voting power of Legacy OH Holdings Inc. has decreased from 11.19% to 10.10% due to a dilution following a share issue by the company. This change reflects the issuance of additional shares, impacting the company’s shareholder structure and potentially influencing its future strategic decisions.
Vitasora Health Limited has issued 141,516,673 fully paid ordinary shares, as announced in their recent ASX release. This move is part of their ongoing efforts to comply with regulatory requirements and maintain transparency with investors. The issuance of shares without disclosure underlines the company’s adherence to the Corporations Act 2001, ensuring no excluded information is withheld. This strategic decision is expected to bolster Vitasora’s financial standing and support its innovative healthcare solutions, potentially enhancing its market position and stakeholder confidence.
Vitasora Health Limited has announced the issuance of 17,500,000 ordinary fully paid securities, which will be quoted on the ASX. This move is part of a previously announced transaction, potentially enhancing the company’s market presence and liquidity, thereby impacting its stakeholders positively.
Vitasora Health Limited has announced the issuance of 124,016,673 ordinary fully paid securities, which will be quoted on the ASX. This move is part of a previously announced transaction, potentially enhancing the company’s market presence and providing opportunities for stakeholders to engage with the company’s growth strategy.
Vitasora Health Limited has announced an update to its previous announcement regarding the proposed issue of securities. The placement will now be conducted in two tranches, reflecting a strategic adjustment in their approach to capital raising. This update may impact the company’s financial strategy and stakeholder interests as it navigates the securities issuance process.
Vitasora Health Limited announced an $11 million capital raise through a placement, with funds received in two tranches. The first tranche of $3.72 million has been settled, and the second tranche will follow after an EGM in August 2025. The capital will support expanded clinical operations, technology enhancements, and business development, ensuring the company is funded through to cash flow breakeven in the second half of FY2026. This financial boost is expected to bolster Vitasora’s growth and commercial rollout, strengthening its position in the healthcare industry.
Vitasora Health Limited has announced a change in the director’s interest notice, specifically concerning Nicholas Smedley. The change involves the lapse of 400,147 VHLO Listed Options held indirectly through various entities, with no new acquisitions or disposals of other securities. This adjustment does not impact the overall number of ordinary shares or options held by the director through different entities, indicating a strategic decision to let the options expire without further action.
Vitasora Health Limited has released a capital raise presentation, emphasizing that the information provided is not comprehensive investment advice and should be considered with caution. The company highlights the inherent risks and uncertainties in developing technology and urges stakeholders not to rely heavily on forward-looking statements as they are subject to change and may not guarantee future performance.
Vitasora Health Limited has successfully raised $11 million through a placement supported by institutional and long-term shareholders, reflecting strong investor confidence in the company’s strategy and execution capabilities. The funds will support Vitasora’s operations until it reaches cash flow breakeven in the second half of fiscal year 2026, enabling the company to expand its clinical operations, enhance its technology platform, and strengthen client relationships. This capital raise positions Vitasora to scale efficiently and generate long-term shareholder value, with additional commercial opportunities anticipated in the near future.
Vitasora Health has expanded its partnership with The Physician Alliance Corporation (TPAC) from a pilot program in Arizona to a full-scale value-based care agreement covering up to 15,000 Medicare patients. This agreement is expected to generate significant new revenue streams for Vitasora through guaranteed care management fees, reimbursed remote patient monitoring services, and performance bonuses linked to quality savings. The partnership positions Vitasora as a leader in the U.S. value-based care market and supports TPAC’s rapid growth strategy, potentially increasing its Medicare patient panel to 100,000 lives within three years. This strategic move enhances Vitasora’s industry positioning and offers a competitive edge for TPAC in attracting new physician practices.
Vitasora Health Limited has announced the expiry of its listed options VHLO on 30 June 2025, with an exercise price of $0.065 per option. Option holders have the choice to exercise, sell, or let the options expire. The company emphasizes the need for holders to act before the official quotation ceases on 24 June 2025. This announcement is crucial for stakeholders as it impacts the potential conversion of 76,186,219 options into fully paid ordinary shares, affecting the company’s capital structure and market positioning.
Vitasora Health Limited has issued a prospectus for the offer of 1,000 shares at a price of $0.045 per share, with the offer closing on June 5, 2025. This prospectus aims to remove secondary trading restrictions on the shares issued under the placement, and the securities offered should be considered speculative.
Vitasora Health Limited announced the release of 35,555,555 fully paid ordinary shares from escrow on June 3, 2025, which were initially issued to institutional and sophisticated investors. This move is in line with the company’s strategic efforts to enhance its financial flexibility and could potentially impact its market positioning by increasing the liquidity of its shares.
Vitasora Health Limited has announced a virtual investor update to discuss significant developments in the United States, which are expected to impact the company’s growth trajectory. The briefing will cover recent progress with U.S. partners, expansion milestones, and upcoming opportunities, highlighting the company’s strategic positioning in the healthcare industry and its potential implications for stakeholders.
Vitasora Health Limited announced a change in the director’s interest, with Nicholas Smedley acquiring 875,000 ordinary shares through a share placement approved at the company’s Extraordinary General Meeting on April 16, 2025. This acquisition reflects a strategic move to strengthen the director’s stake in the company, potentially impacting the company’s governance and signaling confidence in its future prospects.
Vitasora Health Limited has issued 1,750,000 fully paid ordinary shares, as announced in their recent ASX release. This move is part of their ongoing efforts to comply with regulatory requirements and maintain transparency with investors. The issuance of shares without disclosure under certain provisions of the Corporations Act indicates a strategic approach to capital management, potentially impacting the company’s financial structure and market positioning.
Vitasora Health Limited has announced the issuance of 1,750,000 fully paid ordinary securities, which will be quoted on the ASX as of May 15, 2025. This move is part of previously announced transactions and is expected to enhance the company’s market presence and provide additional capital for growth initiatives.